Independent assessment validates GoodRx’s continued leadership in cybersecurity and data protection

GoodRx (Nasdaq: GDRX), the leading platform for prescription savings in the U.S., today announced it has earned its 2026 certification status for HITRUST i1 Certification for its prescription savings platform hosted on Amazon Web Services (AWS). This certification shows continuous dedication to GoodRx’s prior HITRUST achievement and underscores the company’s ongoing commitment to safeguarding sensitive healthcare information.

The HITRUST i1 Certification demonstrates that GoodRx has met requirements defined by leading cybersecurity and regulatory frameworks, confirming that strong controls are in place to protect sensitive data and manage risk effectively. The certification covers GoodRx’s AWS-hosted drug savings platform, including data centers in California, Ohio, Oregon, and Virginia.

“HITRUST Certification validates our approach to protecting sensitive health data at scale,” said Nitin Shingate, Chief Technology Officer at GoodRx. “Security and trust remain foundational to how we build and operate our platform.”

This achievement reflects independent third-party testing of GoodRx controls for protecting against current and emerging threats.

“Earning HITRUST Certification demonstrates organizational commitment to managing information risk and protecting sensitive data through a rigorous, proven assurance process,” said Gregory Webb, CEO of HITRUST. “This achievement reflects GoodRx’s proactive approach to cybersecurity and trust.”

About GoodRx

GoodRx is the leading platform for medication savings in the U.S., used by nearly 25 million consumers and over one million healthcare professionals annually. Uniquely situated at the center of the healthcare ecosystem, GoodRx connects consumers, healthcare professionals, payers, PBMs, pharma manufacturers, and retail pharmacies to make saving on medications easier. By reducing friction and inefficiencies, GoodRx helps consumers save time and money when filling prescriptions so they can get the care they deserve. Since 2011, GoodRx has helped Americans save over $100 billion on the cost of their medications.

​GoodRx periodically posts information that may be important to investors on its investor relations website at https://investors.goodrx.com. We intend to use our website as a means of disclosing material nonpublic information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors and potential investors are encouraged to consult GoodRx’s website regularly for important information, in addition to following GoodRx’s press releases, filings with the Securities and Exchange Commission (the “SEC”) and public conference calls and webcasts. The information contained on, or that may be accessed through, GoodRx’s website is not incorporated by reference into, and is not a part of, this press release.

GoodRx Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding anticipated consumer savings, convenience and accessibility; the expected benefits and value of our HITRUST i1 certification; and our plans, expectations and objectives. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, risks relating to our ability to achieve broad market education and change consumer purchasing habits; changes in medication pricing and pricing structures; our reliance on a limited number of industry participants; and the important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024, and our other filings with the SEC. Any such forward-looking statements are based on current expectations, projections and estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260202274553/en/